Pharma, Medical & Biotech Global Trend Report
Mergermarket has released its Global Pharma, Medical & Biotech (PMB) trend report for the first half (H1) of 2015. Take a look at the full report HERE.
A few key findings include:
-Global PMB M&A activity hit the highest half-year value on Mergermarket record (since 2001 in H1 2015), with US$ 211.2bn-worth of deals representing a 2.7% increase from H1 2014 (US$ 205.7bn). While the deal count has seen two consecutive quarters of decline, the sector is still seeing high valued deals, demonstrated by Q2 2015’s 270 deals valued at US$ 118.7bn, increasing 28.5% by value from Q1 2015 (US$ 92.4bn)
-The slight increase during the first half of 2015 compared to the start of 2014 was driven by a burst of activity in the Pharma sub-sector. Pharma’s 168 deals valued at US$ 159.1bn increased 58.6% from H1 2014’s 176 deals worth US$ 100.3bn, accounting for 75.3% of total PMB M&A value in H1 2015
-The ability to command high price tags on companies was evident in the US where firms have been seeing the average adjusted EBITDA multiples jump from 16.7x in 2014 to22.3x in H1 2015. The country continued to lead the high level of activity in the global PMB sector with a 69.2% market share from US$ 142bn-worth of deals during the first six months of the year, reaching the second highest H1 value on record after 2009 (US$ 166.6bn)
Total Page Views: 966
